Intra-cellular Therapies, Inc.

This early-stage study tested a long-acting injectable form of the drug lumateperone in 52 adults with stable schizophrenia or schizoaffective disorder. The goal was to see how the body processes the drug and whether it is safe. Participants received a single shot, and researcher…

This study tested a new medicine called ITI-007 in 696 people with schizophrenia who were having a sudden worsening of symptoms. For 6 weeks, some received ITI-007, some a placebo, and some an active comparator. The main goal was to see if ITI-007 reduces symptoms like hallucinat…

This study looked at how safe and tolerable the drug lumateperone is for teenagers aged 13 to 17 with schizophrenia or schizoaffective disorder. Researchers gave the drug to 26 teens and monitored side effects and how the drug moves through the body. The goal was to gather early …

This study tested whether a new drug called ITI-007 can reduce symptoms of schizophrenia better than a placebo. 450 adults with worsening psychosis took either the drug or a placebo for 28 days. The main goal was to see if their symptoms improved, measured by a standard psychiatr…

This study tested a new medication called ITI-007 (Lumateperone) to see if it can safely ease depression in people with bipolar I or II disorder. About 550 adults experiencing a major depressive episode took either the drug or a placebo for 6 weeks. The main goal was to measure c…

This study tested whether a new drug called ITI-007 can reduce symptoms of schizophrenia during a sudden worsening of psychosis. 335 adults with schizophrenia were randomly assigned to receive ITI-007, a placebo, or another antipsychotic. The main goal was to measure changes in s…

This study looked at whether adding the drug lumateperone to standard antidepressants is safe for people with major depressive disorder. Over 800 adults took the combination for 26 weeks, and researchers tracked side effects and mood changes. The goal was to see if this add-on th…

This early-stage study tested the safety and how the body handles a new drug called ITI-333. It involved 32 healthy adults aged 18 to 45 who took either the drug or a placebo daily for 14 days. The goal was to check for side effects and measure drug levels in the blood, not to tr…

This early-stage study tested a single dose of the experimental drug ITI-333 in 12 healthy adults aged 18-45. Researchers used PET brain scans to see how much of the drug attached to a specific brain receptor (5-HT2A) and checked safety and drug levels in the blood. The goal was …